3rd Tropé-Kolstad Meeting

Ovarian Cancer: Controversies in Management

SCIENTIFIC PROGRAM

09:00-09:05: Welcome
Dr. Gunnar Kristensen, MD, PhD, Vice Chairman of the Department of Gynecological Oncology, the Norwegian Radium Hospital (Norway),

Molecular Classification of Ovarian Carcinoma

Chair: Dr. Janne Kærn, MD, PhD (Norway), Prof. Ben Davidson, MD, PhD (Norway)

09:05-09:25: Update in Germ Cell Tumors: Watch and Wait or Watch and Worry?
Prof. David M. Gershenson, MD (USA)

09:25-09:35: Discussion

09:35-09:55: Germ Cell Tumors – The Norwegian Experiences
Dr. Olesya Solheim, MD (Norway)

09:55-10:00: Discussion

Ovarian Cancer Prevention

10:00-10:20: Oral Contraceptives as Ovarian Cancer Prevention
Prof. Christian Marth, MD, PhD (Austria)

10:20-10:25: Discussion

Modern Medical Treatment of Ovarian Cancer

10:25-10:45: Target Therapy: Is There Any Role in Gynecological Cancer?
Prof. Robert Coleman, MD (USA)

10:45-10:50: Discussion

10:50-11:20: Coffee break

Controversial Surgical Issues in Ovarian Cancer Treatment

Chair: Dr. M Bilal Sert, MD (Norway), Dr. Tone Skeie-Jensen, MD, PhD (Norway)

11:20-11:40: Nomogram for Predicting 5-Year Disease-Specific Mortality after Primary Surgery for Epithelial Ovarian Cancer
Prof. Dennis Chi, MD (USA)

11:40-11:45: Discussion

The 3rd Tropé-Kolstad Lecture

Introduction: Prof. Claes G Tropé, MD, PhD (Norway)

11:45-12:45: Epithelial Ovarian Cancer: A Real Challenge for the Next 25 Years!
Prof. David M Gershenson, MD (USA)

12:45-14:00: Lunch

Controversial Surgical Issues in Ovarian Cancer Treatment (cont.)

14:00-14:20: Tertiary Surgery in Recurrent Ovarian Cancer: Is That a Technical Gimmick or Surgical Advance?
Dr. Christina Fotopoulou, MD, PhD (Germany)

14:20-14:25: Discussion

Controversies Concerning Endpoints Phase III Trials in Ovarian Cancer

Chair: Prof. Bjørn Hagen, MD, PhD (Norway), Prof. Helga Salvesen, MD, PhD (Norway)

14:25-14:45: Should Phase III Trials in Ovarian Cancer be Abandoned?
Prof. Ignace Vergote, MD, PhD (Belgium)

14:45-15:05: What Should Be the Endpoints for Trials in Ovarian Cancer?
Prof. Ignace Vergote, MD, PhD (Belgium)

15:05-15:15: Discussion

15:15-15:45: What Are the Treatment Options for Recurrent Ovarian Cancer?
Prof. Jonathan Ledermann, BSc, MD (UK)

15:45-15:50: Discussion

15:50-16:15: Coffee break

Intraperitoneal Therapy for Ovarian Cancer

Chair: Dr. Anne Dørum, MD, PhD (Norway)

16:15-16:45: Does Intraperitoneal Therapy for Ovarian Cancer Have a Future?
Prof. Dennis Chi, MD (USA

16:45-17:15: HIPEC – the Norwegian Radium Hospital Experiences
Dr. Stein Larsen, MD, PhD (Norway)

17:15-17:45: HIPEC – Uppsala Experiences
Ilvars Silins, MD, PhD (Sweden)

17:45-17:55: Discussion

17:55-18:00: Closing remarks

Published Nov. 6, 2012 1:00 PM - Last modified Nov. 6, 2012 1:07 PM